CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

MINNEAPOLIS, July 23, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2026 financial and operating results after market close on Thursday, August 6, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501 [email protected] Media Contact:Emily Meyers CVRx, Inc. 763-416-2853 [email protected]

GlobeNewsWire • Jul 23, 2026

CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last?

CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Jun 29, 2026

CVRx, Inc. (CVRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CVRx, Inc. (CVRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 10, 2026

CVRx Announces Chief Financial Officer Transition

MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Jared Oasheim, the Company's Chief Financial Officer, will be stepping down from his role to pursue other professional opportunities. To support a seamless transition, Mr. Oasheim will remain with the Company until a successor is appointed and remain available as an advisor through February 2027. “Jared has been an integral part of CVRx since 2015, and has made a lasting mark on our company over the past decade” said Kevin Hykes, President and Chief Executive Officer of CVRx. “He led CVRx through its initial public offering and built the disciplined finance organization that supports our commercial growth today, all while staying focused on our mission to improve the lives of patients with heart failure. We are grateful for his many contributions and wish him every success.” “It has been a privilege to help build CVRx alongside such a dedicated team and to play a part in bringing Barostim to more patients,” said Jared Oasheim, Chief Financial Officer of CVRx. “Taking the company public and helping establish its financial foundation has been one of the highlights of my career. I am committed to a seamless transition and look forward to seeing CVRx continue its momentum.” The Company is initiating a search to identify its next Chief Financial Officer. Presentation at Goldman Sachs Healthcare Conference As previously announced, Kevin Hykes and Jared Oasheim will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Wednesday, June 10, 2026 at 8:00 a.m. (ET). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact: Mark Klausner or Mike VallieICR Healthcare443-213-0501 [email protected] Media Contact: Emily MeyersCVRx, [email protected]

GlobeNewsWire • Jun 9, 2026

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

MINNEAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Wednesday, June 10, 2026. The Company's presentation will begin at 8:00 a.m. (ET).

GlobeNewsWire • May 27, 2026

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT).

GlobeNewsWire • May 20, 2026

CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy

CVRX stock gains after Humana adds Medicare Advantage coverage for Barostim therapy, boosting reimbursement momentum and patient access.

Zacks Investment Research • May 18, 2026

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Humana has issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1, 2026. Humana, a national health insurance company with the second largest Medicare Advantage program in the U.S., provides coverage to approximately 5.2 million Medicare Advantage members across 46 states.

GlobeNewsWire • May 14, 2026

Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX)

CVRx (CVRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • May 13, 2026

CVRx Q1 Earnings Call Highlights

CVRx NASDAQ: CVRX reported first-quarter 2026 revenue of $14.8 million, up 20% from the prior-year period, as U.S. growth in its Barostim heart failure business helped the company exceed the high end of its guidance range, executives said on the company's earnings call.

MarketBeat • May 11, 2026